Platinum-sensitive Recurrent Ovarian Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-03-06
Clinical Trial Update: Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial of Iparomlimab/Tuvonralimab with standard chemotherapy and Olaparib in platinum-sensitive recurrent ovarian cancer; currently …